BIOHARVEST SCIENCES INC.
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
The yearly report of certain Canadian companies, filed under a joint US and Canadian system. It is the main yearly account these companies give US investors, largely as filed in Canada.
FY2024 · Filed Mar 31, 2025
Use the contents to explore the available documents and sections.
Contents
EX-99.2 · Analysis:
Analysis:
A 5% appreciation of the USD against the following currencies would have increased (decreased) equity and the income statement by the amounts shown below. This analysis assumes that all other variables, in particular interest rates, remain constant.
For a 5% depreciation of the USD against the relevant currency, there would be an equal and opposite impact on the profit and other equity.
| Linked Currency · As of December 31, 2024 · As of December 31, 2023 | ||||
|---|---|---|---|---|
| Net Assets · Net Impact · Net Assets · Net Impact | ||||
| CAD | (716) | (36) | - | - |
| Euro | - | - | 4 | - |
| NIS | (15,037) | (752) | (4,631) | (232) |
b. Liquidity risks:
Liquidity risk is the risk that arises when the maturity of assets and the maturity of liabilities do not match. An unmatched position potentially enhances profitability but can also increase the risk of loss. The Company has procedures with the object of minimizing such loss by maintaining sufficient cash and other highly liquid current assets and by having available an adequate amount of committed credit facilities. The Company has no material obligation beyond one year except for lease liabilities, installments for equipment purchase agreement disclosed in note 7 (the liability for governmental institutes depends on achieving future revenues) and cash in bank to finance its working capital in the near future.
The following tables detail the Company's remaining contractual maturity for its financial liabilities. The tables have been drawn up based on the undiscounted cash flows of financial liabilities based on the repayment forecast of the management of the company.
| December 31, 2024 | Amortized cost | ||||||
|---|---|---|---|---|---|---|---|
| Book value | Less than one year | 1 to 2 years | 2 to 3 years | 3 to 4 years | > 5 years | Total | |
| Trade accounts payable and Accrued liabilities | (3,926) | (3,926) | - | - | - | - | (3,926) |
| Other accounts payable | (2,325) | (2,325) | - | - | - | - | (2,325) |
| Loans | (3,905) | (3,905) | - | - | - | - | (3,905) |
| Lease Liability | (9,913) | (924) | (1,206) | (1,176) | (1,188) | (14,862) | (19,356) |
| Liability and Provision for Agricultural Research Organization | (2,696) | (2,424) | (272) | - | - | - | (2,696) |
| Total | (22,765) | (13,504) | (1,478) | (1,176) | (1,188) | (14,862) | (32,208) |
| December 31, 2023 | Amortized cost | ||||||
|---|---|---|---|---|---|---|---|
| Book value | Less than one year | 1 to 2 years | 2 to 3 years | 3 to 4 years | > 5 years | Total | |
| Trade accounts payable and Accrued liabilities | (2,236) | (2,236) | - | - | - | - | (2,236) |
| Other accounts payable | (1,527) | (1,527) | - | - | - | - | (1,527) |
| Lease Liability | (1,807) | (457) | (428) | (425) | (425) | (694) | (2,429) |
| Liability and Provision for Agricultural Research Organization | (2,508) | (1,345) | (998) | (165) | - | - | (2,508) |
| Total | (8,078) | (5,565) | (1,426) | (590) | (425) | (694) | (8,700) |
c. Fair value of financial assets and liabilities:
The fair value of the Company's current financial assets and liabilities approximates their carrying amounts as their maturity date is less than 1 year and they do not bear a fixed interest rate.
Reconciliation of fair value measurements that are categorized within Level 3 of the fair value hierarchy:
| Derivative liability - Warrants | 2024 | 2023 |
|---|---|---|
| Balance as of January 1 | 526 | - |
| Issuance of Warrants* | - | 291 |
| Exercise of Warrants | - | - |
| Loss (income) recognized in Profit or loss | 408 | 235 |
| Reclassification as an equity instrument (Note 9) | (934) | - |
| Balance as of December 31 | - | 526 |
| Convertible loan | 2024 | 2023 |
|---|---|---|
| Balance as of January 1 | 20,533 | 8,549 |
| Issuance of Convertible loan | - | 13,517 |
| Conversion of convertible loans | (22,822) | (2,557) |
| Loss recognized in Profit or loss | 3,503 | 1,024 |
| Repayment of principal and accrued interest | (693) | - |
| Reclassification into Loans | (521) | - |
| Balance as of December 31 | - | 20,533 |
*Recognized in profit and loss
d. Financial instruments not measured at fair value:
Financial instruments not measured at fair value include cash and cash equivalents, restricted cash, trade and other accounts receivable, trade and other accounts payable, liability and provision to Agricultural Research Organization, loans and lease liabilities.
Due to their short-term nature, the carrying value of cash and cash equivalents, restricted cash, trade and other accounts receivable, trade and other accounts payable and loans approximate their fair value.
The fair value of Liability and Provision to Agricultural Research Organization for December 31, 2024, and December 31, 2023, is not materially different to the carrying amount, since the interest rate used in the initial recognition is close to current market rates.
e. Capital management:
The Company seeks to maintain a capital structure which enables it to continue as a going concern and which supports its business strategy. The Company's capital is provided by equity rising. The Company manages its capital structure through raising funds from shareholders. The Company has net cash and cash equivalents as of December 31, 2024, of $2,390 (2023 – $5,355). Accordingly, the directors believe that the Company will be able to pay its debts when they fall due, and to fund near term anticipated activities based on receipt from issuance of shares in addition to revenues backlog.
NOTE 17 - Related Parties Transactions:
Related parties including the Company's CEO, CFO, Chairman of the Board and Directors.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.